SCHEMBL1620883

SCHEMBL1620883

CCc1cc(C=O)cc2c1OCOC2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.38
RAB9A P51151 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
POLB P06746 2/20 0.38
RXFP1 Q9HBX9 2/20 0.35
HTT P42858 1/20 0.35
SMPD1 P17405 2/20 0.34
KMT2A Q03164 3/20 0.34
MAPT P10636 3/20 0.34
MEN1 O00255 2/20 0.34
TSHR P16473 2/20 0.34
GAA P10253 2/20 0.34
HPGD P15428 2/20 0.34
NPC1 O15118 1/20 0.34
TDP1 Q9NUW8 3/20 0.33
KDM4E B2RXH2 2/20 0.33
ADRB2 P07550 1/20 0.33
USP2 O75604 1/20 0.32
GALR3 O60755 1/20 0.32
NR2F2 P24468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1620023 0.82 ALDH1A1 (0.36) ALDH1A1RAB9ASMN1; SMN2POLBRXFP1
SCHEMBL2629669 0.81 KDM4E (0.43) ALDH1A1RAB9ASMN1; SMN2POLBSMPD1
SCHEMBL1620646 0.78 ALDH1A1 (0.41) ALDH1A1RAB9ASMN1; SMN2POLBHTT
SCHEMBL5024437 0.77 GALR3 (0.47) ALDH1A1RAB9ASMN1; SMN2POLBRXFP1
SCHEMBL1620477 0.77 SMPD1 (0.45) ALDH1A1RAB9ASMN1; SMN2POLBRXFP1
SCHEMBL12467242 0.77 ALDH1A1 (0.51) ALDH1A1RAB9ASMN1; SMN2POLBRXFP1
SCHEMBL12824889 0.69 ALDH1A1 (0.39) ALDH1A1RAB9ASMN1; SMN2POLBRXFP1
SCHEMBL10843574 0.68 ALDH1A1 (0.59) ALDH1A1RAB9AKMT2AMAPTMEN1
SCHEMBL31024004 0.68 ALDH1A1 (0.59) ALDH1A1RAB9AKMT2AMAPTMEN1
SCHEMBL1525798 0.67 ALDH1A1 (0.49) ALDH1A1RAB9ASMN1; SMN2POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194046-B1 Triazolone derivative EISAI R&D MAN CO LTD (JP) 2012-05-09 EP disclosed
US-8163787-B2 Triazolone derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-04-24 US disclosed
US-8163787-B2 Triazolone derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-04-24 US disclosed
US-8163787-B2 Triazolone derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-04-24 US disclosed
US-20110112109-A1 TRIAZOLONE DERIVATIVES CLARK RICHARD 2011-05-12 US disclosed
US-20110112109-A1 TRIAZOLONE DERIVATIVES CLARK RICHARD 2011-05-12 US disclosed
US-20110112109-A1 TRIAZOLONE DERIVATIVES CLARK RICHARD 2011-05-12 US disclosed
US-7928228-B2 Triazolone derivatives EISAI CO., LTD. (JP) 2011-04-19 US disclosed
US-7928228-B2 Triazolone derivatives EISAI CO., LTD. (JP) 2011-04-19 US disclosed
US-7928228-B2 Triazolone derivatives EISAI CO., LTD. (JP) 2011-04-19 US disclosed
US-7816522-B2 Triazolone derivatives EISAI CO., LTD. (JP) 2010-10-19 US disclosed
US-7816522-B2 Triazolone derivatives EISAI CO., LTD. (JP) 2010-10-19 US disclosed
US-20100190783-A1 TRIAZOLONE DERIVATIVES CLARK RICHARD 2010-07-29 US disclosed
US-20100190783-A1 TRIAZOLONE DERIVATIVES CLARK RICHARD 2010-07-29 US disclosed
US-20100190783-A1 TRIAZOLONE DERIVATIVES CLARK RICHARD 2010-07-29 US disclosed
EP-2194046-A1 Triazolone derivative Eisai R&D Management Co., Ltd. (JP) 2010-06-09 EP disclosed
EP-2000465-A1 TRIAZOLONE DERIVATIVE Eisai R&D Management Co., Ltd. (JP) 2008-12-10 EP disclosed
US-20080015199-A1 Triazolone derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-01-17 US disclosed
US-20080015199-A1 Triazolone derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-01-17 US disclosed
US-20080015199-A1 Triazolone derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190783-A1 TRIAZOLONE DERIVATIVES H1-0, H1-10, H1-2 ALDH1A1 701/4885RAB9A 624/4885SMN1; SMN2 3953/4885
US-20110112109-A1 TRIAZOLONE DERIVATIVES H1-10, H1-0, H1-2 ALDH1A1 905/4885RAB9A 695/4885SMN1; SMN2 4234/4885
US-20080015199-A1 Triazolone derivatives F3, F12, F2 ALDH1A1 710/4885RAB9A 868/4885SMN1; SMN2 3935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.